UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 10, 2004
Chiron Corporation
(Exact name of registrant as specified in its charter)
|
Delaware |
|
0-12798 |
|
94-2754624 |
|
(State or other |
|
(Commission |
|
(IRS Employer |
|
jurisdiction of |
|
File Number) |
|
Identification No.) |
|
incorporation) |
|
|
|
|
|
|
|
|
|
|
|
4560 Horton Street, Emeryville, CA |
|
94608 |
||
Registrant’s telephone number, including area code (510) 655-8730
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8 — Other Events
Item 8.01. Other Events
On December 10, 2004, Chiron Corporation announced via press release that it had received a warning letter from the U.S. Food and Drug Administration (FDA) in connection with the agency’s October 2004 inspection of Chiron’s Liverpool facility, which produces FLUVIRIN® influenza virus vaccine.
A copy of Chiron’s press release is attached hereto as Exhibit 99.1.
(c) Exhibits
99.1 Press release issued on December 10, 2004.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
CHIRON CORPORATION |
|
|
|
|
(Registrant) |
|
|
|
|
|
|
|
Date: December 10, 2004 |
|
By: |
William G. Green |
|
|
|
|
William G. Green |
|
|
|
|
Sr. Vice President; Secretary and Special Counsel to the CEO |